Status:
COMPLETED
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
Lead Sponsor:
Eli Lilly and Company
Conditions:
Social Phobia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.
Eligibility Criteria
Inclusion
- Male or female outpatients at least 18 years of age and not more than 65 years of age.
- Must sign the informed consent document.
- Present at Visit 1 with social anxiety disorder based on a Clinical Global Impression-Severity score of greater than or equal to 4.
- Females of childbearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use both a reliable primary method of birth control.
- Judged to be reliable and willing to keep all appointments for clinic visits, tests, and procedures required by the protocol.
Exclusion
- Have any comorbid Axis I disorders (such as major depression, obsessive compulsive disorder, post-traumatic stress disorder, or panic disorder), in the opinion of the investigator, if the disorder occurred within the last 6 months.
- Have had any previous or current diagnoses of bipolar disorders, schizophrenia, or other psychotic disorders.
- Have the presence of an Axis II disorder, except avoidant personality disorder.
- Have a serious medical illness.
- Have abnormal thyroid-stimulating hormone (TSH) concentrations or are taking thyroid supplements.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT00191022
Start Date
December 1 2004
End Date
January 1 2007
Last Update
February 13 2007
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Burbank, California, United States, 91506
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Newport Beach, California, United States, 92660
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Denver, Colorado, United States, 80212
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
New Britain, Connecticut, United States, 06052